Eisai finds an exit from Aduhelm, with small royalties if it ever nabs coverage
With less than a month to go to the final national coverage determination from CMS, Biogen’s Japanese partner Eisai is essentially cutting its losses on their FDA-approved Alzheimer’s drug.
The two companies on Wednesday unveiled a reworked partnership for their controversial Alzheimer’s drug Aduhelm, which won a contentious accelerated approval last summer, limped onto the market and now may only be covered in clinical trials if the draft CMS decision gets finalized as is on April 11.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.